JEFFERSON CITY, Mo. (AP) — State officials say Missouri’s Medicaid
program will save an estimated $4.2 million in fiscal year 2016 by using
a newer, cheaper drug to treat hepatitis C.
The state joined a group of 25 other states to receive rebates on
Viekira from drug maker AbbVie. The state in most cases will provide
that drug instead of Gilead Science’s Sovaldi in an agreement announced
The expensive treatment with Sovaldi, about $84,000 for a normal
course, was cited as one driver of increased Medicaid costs for the
state in 2015 by the state budget director.
Labels: Missouri Medicaid, Viekira Pak